Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Rises By 172.7%

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 56,514 shares, an increase of 172.7% from the August 15th total of 20,724 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average daily trading volume, of 950,731 shares, the days-to-cover ratio is presently 0.1 days.

Evaxion A/S Stock Down 1.9%

Shares of EVAX traded down $0.06 during trading hours on Monday, hitting $3.07. 21,866 shares of the company were exchanged, compared to its average volume of 97,450. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.06 and a current ratio of 5.06. The company has a market cap of $25.60 million, a PE ratio of -2.54 and a beta of 0.26. The firm’s 50 day moving average is $3.09 and its 200-day moving average is $3.55. Evaxion A/S has a 52 week low of $2.77 and a 52 week high of $12.15.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Hedge Funds Weigh In On Evaxion A/S

Institutional investors have recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Evaxion A/S during the 1st quarter worth $112,000. Renaissance Technologies LLC acquired a new position in Evaxion A/S during the 1st quarter worth $146,000. Finally, Rathbones Group PLC bought a new stake in Evaxion A/S during the first quarter valued at about $170,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.